ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the launch of its ViewMate™ Z Intracardiac Ultrasound System and ViewFlex™ Plus Intracardiac Echocardiography (ICE) Catheter.
The ViewMate Z System is designed for real-time image guidance and visualization of the cardiac anatomy. The system is able to deliver fast, high-fidelity images that help direct diagnosis or therapy during complex electrophysiology procedures. The system is compatible with the new ViewFlex™ Plus ICE Catheter, which offers improved one-handed control, steering angles up to 120° and enhanced tip stability. The ViewMate Z System is designed to allow clinicians to better visualize a patient’s cardiac anatomy and the effects of treatment in real-time.
One of the industry's smallest cart-based systems, the ViewMate Z System offers greater portability and optimizes vital lab space while reducing obstructions in a clinician’s workflow. The system was designed, developed and provided through St. Jude Medical’s development and distribution agreement with ZONARE Medical Systems, a leading provider of high-end ultrasound systems.
"The ViewMate Z System offers clear visualization of patient anatomy and in turn provides the opportunity for a more effective procedure for the patient. It also has a unique ability to quickly produce exceptional images in a compact, cart-based system, improving on the effectiveness and efficiency of current ICE systems,” said Jane J. Song, president of the St. Jude Medical Atrial Fibrillation Division. “This system is just the first of many products we intend to launch focusing on better imaging tools that put more control in the hands of physicians.”
ZONARE Medical System’s unique Zone Sonography™ enables the ViewMate Z System to provide premium image quality, performance and features, as well as advanced image processing capabilities without the limitations of current systems. Conventional ultrasound systems acquire and process echo data line-by-line and therefore are limited by the time required for sound propagation in the patient’s body. Zone Sonography technology is a new approach to echo data acquisition and image formation. It acquires ultrasound data very quickly in a relatively small number of large zones, each of which contain a volume of data equivalent to many lines in a conventional system. Zone Sonography technology acquires data up to ten times faster than conventional systems.
Ultrasound technology allows physicians to produce high-resolution intracardiac images. These images help guide physicians in performing a variety of procedures such as radiofrequency (RF) ablation to treat irregular heart rhythms and in closing defects such as patent foramen ovale (PFO), a small hole or opening in the wall between the two upper chambers of the heart (the atria). Clear views inside the heart also help reduce the time that it takes physicians to perform such procedures, providing patients an opportunity to recover more quickly and potentially enhancing hospital productivity.
Ultrasound imaging systems work by transmitting high-frequency sound waves through a transducer on the tip of a catheter. The sound waves reflect off structures inside the heart and the transducer collects and converts them back into electric energy to produce anatomical images. This ultrasound imaging process can also help to eliminate unnecessary fluoroscopy (X-ray) exposure to the patient and physician.
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended October 2, 2010. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.